ReviewJournal of perinatology : official journal of the California Perinatal Association2026
Surfactant replacement therapy in preterm infants with congenital heart disease: Physiological concepts and therapeutic considerations.
Review in Journal of perinatology : official journal of the California Perinatal Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A prevalence rate of 8.8/1000 live-births for congenital heart disease has been reported. The clinical outlook of these infants is dependent on transition from intra-uterine life to postnatal life. Preterm infants are also commonly administered surfactant to manage respiratory distress syndrome. This physiology-based narrative describes optimal oxygen saturation, mechanical ventilation practices and circulatory imbalances that might happen after surfactant administration in preterm infants with congenital heart disease. Clinicians may consider higher oxygen requirement thresholds for surfactant therapy in this select cohort, in comparison to infants without congenital heart disease. The interplay between surfactant deficiency, surfactant replacement therapy, and the unique interaction with underlying congenital heart disease represents a knowledge gap. This perspectives article discusses the haemodynamic vulnerability of preterm infants and discusses the circulatory impact of surfactant in premature infants without and with structural heart disease. We provide physiology-based suggestions for duct-dependent lesions, parallel circulations and other structural heart disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.